Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
RAF265
i
Other names:
RAF265, CHIR-265
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(7)
News
Trials
Company:
Novartis
Drug class:
BRAF inhibitor, VEGFR-2 inhibitor
Related drugs:
‹
vemurafenib (212)
dabrafenib (211)
PLX4720 (65)
encorafenib (63)
VS-6766 (27)
FORE-8394 (20)
ERAS-254 (7)
GDC 0879 (6)
RXDX-105 (5)
RAF709 (3)
HI-511 (1)
SB-590885 (1)
BGB-3245 (1)
PF-07284890 (1)
ARQ 736 (0)
ASN003 (0)
BDTX-4933 (0)
BMS-908662 (0)
PF-07799933 (0)
RX208 (0)
NSC311152 (0)
rivoceranib (82)
ramucirumab (59)
SU5614 (6)
tivozanib (3)
GSK1363089 (2)
GB-103 (2)
KC1036 (1)
OSI-930 (1)
BMS-582664 (1)
E7050 (1)
pegdinetanib (0)
BMS690514 (0)
BTG-002814 (0)
C019199 (0)
JI-101 (0)
JY025 (0)
MG-D-1509 (0)
MSB0254 (0)
NCE 401 (0)
R1530 (0)
VEGFR2-169 (0)
VXM01 (0)
DCC-2701 (0)
Gensci048 (0)
gentuximab (0)
TTAC-0001 (0)
TSU-68 (0)
AK109 (0)
SYHA1817 (0)
ASA404 (0)
vemurafenib (212)
dabrafenib (211)
PLX4720 (65)
encorafenib (63)
VS-6766 (27)
FORE-8394 (20)
ERAS-254 (7)
GDC 0879 (6)
RXDX-105 (5)
RAF709 (3)
HI-511 (1)
SB-590885 (1)
BGB-3245 (1)
PF-07284890 (1)
ARQ 736 (0)
ASN003 (0)
BDTX-4933 (0)
BMS-908662 (0)
PF-07799933 (0)
RX208 (0)
NSC311152 (0)
rivoceranib (82)
ramucirumab (59)
SU5614 (6)
tivozanib (3)
GSK1363089 (2)
GB-103 (2)
KC1036 (1)
OSI-930 (1)
BMS-582664 (1)
E7050 (1)
pegdinetanib (0)
BMS690514 (0)
BTG-002814 (0)
C019199 (0)
JI-101 (0)
JY025 (0)
MG-D-1509 (0)
MSB0254 (0)
NCE 401 (0)
R1530 (0)
VEGFR2-169 (0)
VXM01 (0)
DCC-2701 (0)
Gensci048 (0)
gentuximab (0)
TTAC-0001 (0)
TSU-68 (0)
AK109 (0)
SYHA1817 (0)
ASA404 (0)
›
Associations
(7)
News
Trials
Filter by
Latest
4years
CHIR-265-MEL01: A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma (clinicaltrials.gov)
P1/2, N=104, Completed, Novartis Pharmaceuticals | Phase classification: P2 --> P1/2
4 years ago
Clinical • Phase classification
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
RAF265
almost7years
MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations (clinicaltrials.gov)
P1, N=69, Completed, Novartis Pharmaceuticals | Active, not recruiting --> Completed
almost 7 years ago
Clinical • Trial completion
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
|
BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600
|
Mektovi (binimetinib) • RAF265
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login